Anika Therapeutics, Inc. — fact timeline

Anika Therapeutics, Inc. reported fiscal year 2026 results: revenue $114 to $122.5 million. Guidance reaffirmed.

“Fiscal 2026 Guidance Anika is maintaining the previously provided 2026 guidance: Total Company Revenue between $114 and $122.5 million, up 1% to 9% year over year Commercial Channel, $53 to $58 million, representing growth of 10% to 20% year over year OEM Channel, $61 to $64.5 million, flat to modestly lower year over year Adjusted EBITDA as a percent of revenue between 5% and 10%, reflecting higher revenues and reduced expenses offset by modestly lower U.S. pricing dynamics.”

Anika Therapeutics, Inc. reported first quarter 2026 results: revenue $29.6 million, net income $5.1 million loss, EPS ($0.37) per diluted share.

“First Quarter 2026 Continuing Operations Financial Summary Revenue $29.6 million, up 13% year over year Commercial Channel revenue $12.6 million, up 12% OEM Channel revenue $17.0 million, up 14% Gross margin 64.2% Operating expenses $24.5 million, including $4.9 million of one-time severance expenses GAAP loss from continuing operations $5.1 million, ($0.37) per diluted share”

Glenn R. Larsen resigned as Class II member of the Board at Anika Therapeutics, Inc..

“On April 24, 2026, both William R. Jellison, a Class I member of the Board of Directors (the "Board") of the Company, and Glenn R. Larsen, Ph.D., a Class II member of the Board, notified the Board of their resignation from the Board, including from all committees on which each serves effective as of the Company's 2026 annual meeting of stockholders (the "2026 Annual Meeting").”

William R. Jellison resigned as Class I member of the Board of Directors at Anika Therapeutics, Inc..

“On April 24, 2026, both William R. Jellison, a Class I member of the Board of Directors (the "Board") of the Company, and Glenn R. Larsen, Ph.D., a Class II member of the Board, notified the Board of their resignation from the Board, including from all committees on which each serves effective as of the Company's 2026 annual meeting of stockholders (the "2026 Annual Meeting").”

Anne Nunes departed as Chief Operations Officer at Anika Therapeutics, Inc..

“On April 4, 2025, Anika Therapeutics, Inc. (the “Company”) announced the departure of Anne Nunes, Chief Operations Officer, effective April 25, 2025.”

Anika Therapeutics, Inc. completed a disposition involving Medacta Americas Manufacturing, Inc. for $4,500,000 in cash (closed 2025-03-07).

“Agreement”), by and among the Company, Parcus and Buyer (the “Transaction”). As consideration for the Transaction, at closing, the Buyer delivered to the Company a payment of $4,500,000 in cash. Pursuant to the Purchase Agreement, the aggregate consideration is subject to customary post-closing adjustments. --- EX-99.1 (PRESS RELEASE) --- EX-99.1 2 exh_991.htm”

Anika Therapeutics, Inc. completed a disposition involving Phoenix Brio, Incorporated for ten-year non-interest bearing promissory note in the principal amount of $7,000,000 (closed 2024-10-31).

““Transaction”). As consideration for the Transaction, at closing, the Buyer delivered to the Company a ten-year non-interest bearing promissory note in the principal amount of $7,000,000. Under the terms of the Purchase Agreement, the Company is also eligible to receive: (i) for each calendar quarter, an amount equal to a percentage of the net sales (the “Revenue”

Joseph Capper was appointed as Director at Anika Therapeutics, Inc..

“the Board of the Company increased its size from eight to ten directors and appointed (i) Mr. Jellison to the Board as a Class I director, with a term expiring at 2024 Annual Meeting and (ii) Mr. Capper to the Board as a Class II director, with a term expiring at the Company’s 2025 annual meeting of stockholders.”

William Jellison was appointed as Director at Anika Therapeutics, Inc..

“the Board of the Company increased its size from eight to ten directors and appointed (i) Mr. Jellison to the Board as a Class I director, with a term expiring at 2024 Annual Meeting and (ii) Mr. Capper to the Board as a Class II director, with a term expiring at the Company’s 2025 annual meeting of stockholders.”

Michael Levitz resigned as Executive Vice President, Chief Financial Officer and Treasurer at Anika Therapeutics, Inc..

“who tendered his resignation on May 2, 2024”

Stephen Griffin was appointed as Executive Vice President, Chief Financial Officer and Treasurer at Anika Therapeutics, Inc..

“announced that Stephen Griffin would be joining the Company as its Executive Vice President, Chief Financial Officer and Treasurer, effective June 3, 2024”

Anika Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $40.5 million, net income $(4.5) million, or ($0.31) per share, EPS $0.09 per diluted share. Guidance reaffirmed.

“orthopedics, today reported financial results for its first quarter ended March 31, 2024. First Quarter 2024 Financial Summary Revenue in the first quarter of 2024 was $40.5 million, up 7% compared to $37.9 million in the first quarter of 2023. OA Pain Management revenue of $24.3 million, up 7% Joint Preservation and Restoration revenue of $13.8 million, up”

Anika Therapeutics, Inc. reported fiscal year ended December 31, 2023 results: revenue $166.7 million, net income ($82.7) million, EPS ($5.64) per share. Guidance initiated.

“Revenue for fiscal 2023 increased 7% to $166.7 million, compared with $156.2 million in 2022. OA Pain Management revenue of $101.9 million, up 11% Joint Preservation and Restoration revenue of $54.9 million, up 9% Non-Orthopedic revenue of $9.9 million, down 29% Gross margin was 62%, including $6.2 million of non-cash acquisition-related intangible asset amortization and $0.7 million of product rationalization charges. Adjusted gross margin 1 , excluding these charges, was 66%. Including the fourth quarter non-cash impairment charge, net loss was ($82.7) million, or ($5.64) per share, compared to net loss of ($14.9) million, or ($1.02) per share, in 2022. Net loss also included $18.1 million, or ($1.23) per share, for charges associated with product rationalization, acquisition related amortization, discontinuation of software development, Parcus arbitration settlement and shareholder activism. Adjusted net loss 1 for the year was ($4.3) million, or ($0.30) per share, compared to adjus”

Anika Therapeutics, Inc. reported fourth quarter ended December 31, 2023 results: revenue $43.0 million, net income ($63.0) million, EPS ($4.30) per share. Guidance initiated.

“Revenue in the fourth quarter of 2023 was $43.0 million, up 8% compared to $39.6 million in the fourth quarter of 2022. OA Pain Management revenue of $25.1 million, up 12%, on growing global commercial adoption and some order timing Joint Preservation and Restoration revenue of $15.3 million, up 7% Non-Orthopedic revenue of $2.6 million, down 8% Gross margin was 61%, including $1.6 million of non-cash acquisition-related intangible asset amortization; Adjusted gross margin 1 was 65%. Recorded a non-recurring, non-cash impairment charge in the fourth quarter of $62.2 million for the intangible assets associated with the Q1-2020 acquisitions of Arthrosurface and Parcus Medical. Including the non-cash impairment charge, net loss was ($63.0) million, or ($4.30) per share, compared to net loss of ($4.9) million, or ($0.34) per share, in the prior year period. Adjusted net income 1 was $0.8 million, or $0.05 per diluted share, compared to adjusted net loss 1 of ($3.0) million, or ($0.21) per”

John B. Henneman, III was appointed as Chair of the Board at Anika Therapeutics, Inc..

“In connection with Mr. Thompson’s planned retirement, John B. Henneman, III, an independent director of the Company’s Board since 2020, has been appointed Chair of the Board, effective immediately.”

Jeffery S. Thompson departed as Director at Anika Therapeutics, Inc..

“On February 24, 2024, Jeffery S. Thompson notified Anika Therapeutics, Inc. (the “Company”) of his intention to retire from the Board of Directors (the “Board”) after 13 years of dedicated service at the end of his current term.”

Anika Therapeutics, Inc. updated its the third quarter ended September 30, 2023 guidance (raised).

“On November 2, 2023, Anika Therapeutics, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2023.”

Anika Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $44.3 million, net income ($2.7) million, or ($0.19) per share, EPS ($0.19) per share. Guidance raised.

“Revenue in the second quarter of 2023 was $44.3 million, up 12% compared to $39.7 million in the second quarter of 2022.”

Anika Therapeutics, Inc. shareholders approved Amendment to the 2017 Amended and Restated Stock Incentive Plan to increase authorized shares by 435,000 at the 2023-06-14 meeting.

“Stockholders voted as follows with respect to this proposal: For Against Abstain Broker Non-Votes 9,807,584 2,331,160 12,991 1,168,309”

Anika Therapeutics, Inc. shareholders approved Non-binding advisory vote on frequency of future advisory votes on executive compensation at the 2023-06-14 meeting.

“Stockholders voted, on a non-binding, advisory basis, as follows with respect to the frequency of future advisory votes on compensation paid to the Company's named executive officers: 1 Year 2 Years 3 Years Abstain 11,078,317 3,067 1,038,679 31,672”

Anika Therapeutics, Inc. shareholders approved Non-binding advisory vote to approve compensation of named executive officers at the 2023-06-14 meeting.

“Stockholders voted as follows with respect to this proposal: For Against Abstain Broker Non-Votes 11,873,054 227,519 51,162 1,168,309”

Anika Therapeutics, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-14 meeting.

“Stockholders voted as follows with respect to this ratification proposal: For Against Abstain Broker Non-Votes 13,279,828 27,825 12,391 0”

Anika Therapeutics, Inc. shareholders approved Election of three Class III directors at the 2023-06-14 meeting.

“Stockholders voted as follows with respect to election of each of the director nominees identified in the Proxy Statement: Nominee For Against Abstain Broker Non-Votes Gary P. Fischetti 12,032,739 106,519 12,477 1,168,309 John B. Henneman, III 11,054,795 1,079,499 17,441 1,168,309 Susan L. N. Vogt 11,721,294 417,401 13,040 1,168,309”

Anne Nunes was appointed as Senior Vice President, Chief Operations Officer at Anika Therapeutics, Inc..

“On June 14, 2023, the Board appointed Anne Nunes, age 54, as the Company’s Senior Vice President, Chief Operations Officer, effective as of June 19, 2023.”

Anika Therapeutics, Inc. reported fiscal year 2023 results: revenue between $158 million and $163 million. Guidance reaffirmed.

“Fiscal 2023 Revenue Outlook The Company continues to expect its overall revenue for fiscal year 2023 to be between $158 million and $163 million, representing growth of 1% to 4% compared to 2022, as growth in OA Pain Management and Joint Preservation and Restoration is offset by lower ancillary Non-Orthopedic revenues*.”

Anika Therapeutics, Inc. reported first quarter ended March 31, 2023 results: revenue $37.9 million, net income ($10.4) million, EPS ($0.71) per share.

“First Quarter 2023 Financial Summary Revenue in the first quarter of 2023 was $37.9 million, up 3% compared with $36.7 million in the first quarter of 2022. Osteoarthritis (OA) Pain Management 1 revenue of $22.6 million, up 8% Joint Preservation and Restoration revenue of $13.5 million, up 11% Non-Orthopedic 1 revenue of $1.8 million, down 49% Gross margin was 60%, including $1.6 million of non-cash acquisition-related expenses; Adjusted gross margin 2 was 64%. Net loss was ($10.4) million, or ($0.71) per share, which includes the Parcus Medical unitholder arbitration settlement, as well as shareholder activism and other non-recurring corporate costs, compared to net loss of ($2.9) million, or ($0.20) per share, in the prior year period.”

Anika Therapeutics, Inc. entered into Cooperation Agreement with Caligan Partners LP, Caligan Partners Master Fund LP and David Johnson (collectively with each of their respective affiliates and associates, the 'Investor Group') valued at $20,000,000 (effective 2023-04-13).

“On April 13, 2023, Anika Therapeutics, Inc. (the “Company”) entered into a Cooperation Agreement (the “Cooperation Agreement”) with Caligan Partners LP, Caligan Partners Master Fund LP and David Johnson (collectively with each of their respective affiliates and associates, the “Investor Group”).”

Gary Fischetti was appointed as Class III director at Anika Therapeutics, Inc..

“effective April 13, 2023, the Board of the Company increased its size from seven to eight directors and appointed Mr. Fischetti to the Board as a Class III director”

Anika Therapeutics, Inc. reported fiscal year ended December 31, 2022 results: net income ($14.9) million, EPS ($1.02) per share.

“Revenue for fiscal 2022 increased 6% to $156.2 million, compared with $147.8 million in 2021”

Anika Therapeutics, Inc. reported the fourth quarter ended December 31, 2022 results: net income ($4.9) million, EPS ($0.34) per share.

“Net loss was ($4.9) million, or ($0.34) per share, compared to net loss of ($5.8) million, or ($0.40) per share, in the prior year period.”

Anika Therapeutics, Inc. reported the fourth quarter and year ended December 31, 2022 results: revenue $39.6 million, net income ($4.9) million, EPS ($0.34) per share.

“Revenue in the fourth quarter of 2022 was $39.6 million, up 11% compared with $35.8 million in the fourth quarter of 2021.”

Anika Therapeutics, Inc. reported third quarter ended September 30, 2022 results: revenue $40.3 million, net income ($4.2) million, or ($0.29) per share, EPS ($0.29) per share.

“orthopedics, today reported financial results for its third quarter ended September 30, 2022. Third Quarter 2022 Financial Summary Revenue in the third quarter of 2022 was $40.3 million, up 2% compared with $39.5 million in the third quarter of 2021. OA Pain Management 1 revenue of $25.7 million, down 2% Joint Preservation and Restoration revenue of $11.8”

Sheryl L. Conley was elected as Director at Anika Therapeutics, Inc..

“elected Sheryl L. Conley as a member of the Board effective as of October 28, 2021.”